Document is current
Any future updates will be listed below
-
Authors
Michalon, Aubin https://orcid.org/0000-0002-5246-4881
Hagenbuch, Andreas
Huy, Christian
Varela, Evita https://orcid.org/0000-0003-0224-0449
Combaluzier, Benoit
Damy, Thibaud
Suhr, Ole B. https://orcid.org/0000-0002-1175-2369
Saraiva, Maria J. https://orcid.org/0000-0002-3360-6899
Hock, Christoph
Nitsch, Roger M.
Jan Grimm, https://orcid.org/0000-0002-3898-3298
-
Funding
Funding for this research was provided by:
EC | Eurostars (E!9036)
- License Information
-
More Information
Article History
Received: 24 August 2020
Accepted: 20 April 2021
First Online: 25 May 2021
Competing interests
: A.M., A.H., C. Huy, E.V., B.C., C. Hock, R.M.N. and J.G. are or were (E.V.) employees of Neurimmune. O.B.S. participates in clinical trials for Alnylam and Prothena Pharmaceuticals, and has served in Advisory boards for Pfizer, Alnylam, Akcea, Prothena, and Intellia Pharmaceuticals, and has participated in educational activities sponsored by Alnylam and Akcea Pharmaceuticals. T.D. participates in clinical trials and has served in Advisory boards for Alnylam, Akcea, Pfizer, and Prothena Pharmaceuticals. M.J.S. does not have competing interest.
